ML22160A422
| ML22160A422 | |
| Person / Time | |
|---|---|
| Site: | 07103091 |
| Issue date: | 05/12/2022 |
| From: | Lacasse S BWXT Medical, Ltd |
| To: | Office of Nuclear Material Safety and Safeguards |
| Shared Package | |
| ML22160A277 | List: |
| References | |
| Download: ML22160A422 (2) | |
Text
Mr. Richard Boyle PHMSA/Radioactive Materials Branch U.S. Department of Transport East Building, 2nd Floor, PHH-23, E21-208 1200 New Jersey Avenue S.E.
Washington, D.C. 20590-0001 May 12, 2022
Subject:
Amendment of the Canadian Nuclear Safety Commissions Transport Package Design Approval CDN/2094/B(U)-96 for F-522 to Revision 4 Attn: Mr. Boyle, Further to our request dated September 23, 2021 [1] for limited revalidation of the Canadian Nuclear Safety Commission (CNSC) Transport Certificate CDN/2094/B(U)-96 Rev. 4 for the F-522, BWXT Medical Ltd. is requesting full revalidation of the certificate. Revision 4 was an amendment to add a new configuration (F-522 overpack/F-528 shielding vessel) for the shipment of neutron irradiated Mo-99 target material encapsulated within zircaloy cladding. This change was initially out of scope of the revalidation request, but is now required to support BWXT Medicals plans to manufacture Technicium-99m (Tc-99m) generators.
The current revision of the certificate, Revision 4, was validated by the U.S. Department of Transport (DOT) on October 19, 2021 and we received Competent Authority Certification USA/0820/B(U)-96 Rev. 3 at that time with the statement Only the UK-201 shielding vessel is authorized under Section 2.
Package Description and Authorized Radioactive Contents.
In support of this application, we are providing the copy of Revision 4 of the CNSC transport certificate.
Please let us know if you require further supporting information to authorize the F-528 shielding vessel.
If you have any questions or require any further information, please feel free to contact me by email at slacasse@bwxt.com, or by telephone at 1-613-963-2537.
Respectfully, Shannon Lacasse Senior EHS Compliance Specialist
CC: Tim Mahilrajan (BWXT)
Michael Dorzek (BWXT)
Encl: CDN/2094/B(U)-96 Rev. 4
Reference:
[1] Letter to Mr. Richard Boyle, U.S. Department of Transport, from Shannon Lacasse, BWXT Medical Ltd., Amendment of the Canadian Nuclear Safety Commissions Transport Package Design Approval CDN/2094/B(U)-96 for F-522 to Revision 4, September 23, 2021